Observational studyBMC cancer2026

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China.

Xianan Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.